Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab

British Journal of Haematology

Volumn 149, Issue 6, 2010, Pages 879-889

  Matthews, Katie ^a,b   Lim, Ziyi ^b   Pearce, Laurence ^b   Pagliuca, Antonio ^b   Alejandro Madrigal, J ^a   Mufti, Ghulam J ^b   Barber, Linda D ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alemtuzumab; Dendritic cells; Haematopoietic stem cell transplantation; Lymphocytes; Malignant disease

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN; FLUDARABINE; PREDNISOLONE; PSORALEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKEMIA RELAPSE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTECTION; PUVA; REDUCED INTENSITY CONDITIONING; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 77952693546     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08164.x     Document Type: Article

References (39)

1. Auffermann-Gretzinger, S., Lossos, I.S., Vayntrub, T.A., Leong, W., Grumet, F.C., Blume, K.G., Stockerl-Goldstein, K.E., Levy, R. Shizuru, J.A. (2002) Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood, 99, 1442 1448.
2. Barber, L.D. Madrigal, J.A. (2006) Exploiting beneficial alloreactive T cells. Vox Sanguinis, 91, 20 27.
3. Baron, F., Baker, J.E., Storb, R., Gooley, T.A., Sandmaier, B.M., Maris, M.B., Maloney, D.G., Heimfeld, S., Oparin, D., Zellmer, E., Radich, J.P., Grumet, F.C., Blume, K.G., Chauncey, T.R. Little, M.T. (2004) Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 104, 2254 2262.
4. Baron, F., Maris, M.B., Sandmaier, B.M., Storer, B.E., Sorror, M., Diaconescu, R., Woolfrey, A.E., Chauncey, T.R., Flowers, M.E., Mielcarek, M., Maloney, D.G. Storb, R. (2005) Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Journal of Clinical Oncology, 23, 1993 2003. (Pubitemid 46211379)
5. Beatty, G.L., Smith, J.S., Reshef, R., Patel, K.P., Colligon, T.A., Vance, B.A., Frey, N.V., Johnson, F.B., Porter, D.L. Vonderheide, R.H. (2009) Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation. Clinical and Cancer Research, 15, 4944 4953.
6. Buggins, A.G., Mufti, G.J., Salisbury, J., Codd, J., Westwood, N., Arno, M., Fishlock, K., Pagliuca, A. Devereux, S. (2002) Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood, 100, 1715 1720.
7. Chakrabarti, S., Hale, G. Waldmann, H. (2004) Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here? Transplantation Proceedings, 36, 1225 1227.
8. Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., Mahendra, P., Craddock, C., Parker, A., Hunter, A., Hale, G., Waldmann, H., Williams, C.D., Yong, K., Linch, D.C., Goldstone, A.H. Mackinnon, S. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 99, 1071 1078.
9. Childs, R., Clave, E., Contentin, N., Jayasekera, D., Hensel, N., Leitman, S., Read, E.J., Carter, C., Bahceci, E., Young, N.S. Barrett, A.J. (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood, 94, 3234 3241.
10. Collins, Jr., R.H., Shpilberg, O., Drobyski, W.R., Porter, D.L., Giralt, S., Champlin, R., Goodman, S.A., Wolff, S.N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J.H. Nemunaitis, J. (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology, 15, 433 444.
11. Cooper, M.A., Fehniger, T.A. Caligiuri, M.A. (2001) The biology of human natural killer-cell subsets. Trends in Immunology, 22, 633 640.
12. Dey, B.R., McAfee, S., Colby, C., Sackstein, R., Saidman, S., Tarbell, N., Sachs, D.H., Sykes, M. Spitzer, T.R. (2003) Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation, 9, 320 329.
13. Ho, A.Y., Pagliuca, A., Kenyon, M., Parker, J.E., Mijovic, A., Devereux, S. Mufti, G.J. (2004) Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood, 104, 1616 1623.
14. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringden, O., Rozman, C. Speck, B. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555 562. (Pubitemid 20069191)
15. Kim, D.H., Kim, J.G., Sohn, S.K., Sung, W.J., Suh, J.S., Lee, K.S. Lee, K.B. (2004) Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. British Journal of Haematology, 125, 217 224.
16. Klangsinsirikul, P., Carter, G.I., Byrne, J.L., Hale, G. Russell, N.H. (2002) Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood, 99, 2586 2591.
17. Kolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L. Niederwieser, D. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041 2050.
18. Kumar, S., Chen, M.G., Gastineau, D.A., Gertz, M.A., Inwards, D.J., Lacy, M.Q., Tefferi, A. Litzow, M.R. (2001) Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplantation, 28, 951 956.
19. Le Dieu, R., Taussig, D.C., Ramsay, A.G., Mitter, R., Miraki-Moud, F., Fatah, R., Lee, A.M., Lister, T.A. Gribben, J.G. (2009) Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood, 114, 3909 3916.
20. Lim, Z.Y., Pearce, L., Ho, A.Y., Barber, L., Ingram, W., Usai, M., Tobal, K., Devereux, S., Pagliuca, A. Mufti, G.J. (2007) Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. British Journal of Haematology, 138, 517 526.
21. Matthews, K., Lim, Z., Afzali, B., Pearce, L., Abdallah, A., Kordasti, S., Pagliuca, A., Lombardi, G., Madrigal, J.A., Mufti, G.J. Barber, L.D. (2009) Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. Haematologica, 94, 956 966.
22. Mattsson, J., Uzunel, M., Brune, M., Hentschke, P., Barkholt, L., Stierner, U., Aschan, J. Ringden, O. (2001) Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. British Journal of Haematology, 115, 935 944.
23. McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molina, A.J., Maloney, D.G., Chauncey, T.R., Gooley, T.A., Hegenbart, U., Nash, R.A., Radich, J., Wagner, J.L., Minor, S., Appelbaum, F.R., Bensinger, W.I., Bryant, E., Flowers, M.E., Georges, G.E., Grumet, F.C., Kiem, H.P., Torok-Storb, B., Yu, C., Blume, K.G. Storb, R.F. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 97, 3390 3400.
24. Melenhorst, J.J., Scheinberg, P., Chattopadhyay, P.K., Gostick, E., Ladell, K., Roederer, M., Hensel, N.F., Douek, D.C., Barrett, A.J. Price, D.A. (2009) High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood, 113, 2238 2244.
25. Mohty, M., Avinens, O., Faucher, C., Viens, P., Blaise, D. Eliaou, J.F. (2007) Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica, 92, 1004 1006.
26. Molldrem, J.J., Lee, P.P., Wang, C., Felio, K., Kantarjian, H.M., Champlin, R.E. Davis, M.M. (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine, 6, 1018 1023.
27. Montero, A., Savani, B.N., Kurlander, R., Read, E.J., Leitman, S.F., Childs, R., Solomon, S.R. Barrett, A.J. (2005) Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. British Journal of Haematology, 130, 733 739.
28. Nadal, E., Garin, M., Kaeda, J., Apperley, J., Lechler, R. Dazzi, F. (2007) Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia, 21, 472 479.
29. Peggs, K.S., Thomson, K., Hart, D.P., Geary, J., Morris, E.C., Yong, K., Goldstone, A.H., Linch, D.C. Mackinnon, S. (2004) Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood, 103, 1548 1556.
30. Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Horton, C. Mehta, J. (1998) Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood, 91, 3481 3486.
31. Reddy, V., Iturraspe, J.A., Tzolas, A.C., Meier-Kriesche, H.U., Schold, J. Wingard, J.R. (2004) Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood, 103, 4330 4335.
32. Reddy, P., Maeda, Y., Liu, C., Krijanovski, O.I., Korngold, R. Ferrara, J.L. (2005) A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nature Medicine, 11, 1244 1249.
33. Rezvani, K., Grube, M., Brenchley, J.M., Sconocchia, G., Fujiwara, H., Price, D.A., Gostick, E., Yamada, K., Melenhorst, J., Childs, R., Hensel, N., Douek, D.C. Barrett, A.J. (2003) Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood, 102, 2892 2900.
34. Savani, B.N., Mielke, S., Rezvani, K., Montero, A., Yong, A.S., Wish, L., Superata, J., Kurlander, R., Singh, A., Childs, R. Barrett, A.J. (2007) Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 13, 1216 1223.
35. Schmid, C., Schleuning, M., Schwerdtfeger, R., Hertenstein, B., Mischak-Weissinger, E., Bunjes, D., Harsdorf, S.V., Scheid, C., Holtick, U., Greinix, H., Keil, F., Schneider, B., Sandherr, M., Bug, G., Tischer, J., Ledderose, G., Hallek, M., Hiddemann, W. Kolb, H.J. (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood, 108, 1092 1099.
36. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756 763.
37. Sykes, M., Szot, G.L., Swenson, K.A. Pearson, D.A. (1997) Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nature Medicine, 3, 783 787.
38. Talarn, C., Urbano-Ispizua, A., Martino, R., Perez-Simon, J.A., Batlle, M., Herrera, C., Granell, M., Gaya, A., Torrebadell, M., Fernandez-Aviles, F., Aymerich, M., Marin, P., Sierra, J. Montserrat, E. (2007) Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome. Haematologica, 92, 1655 1663.
39. Ueno, H., Klechevsky, E., Morita, R., Aspord, C., Cao, T., Matsui, T., Di Pucchio, T., Connolly, J., Fay, J.W., Pascual, V., Palucka, A.K. Banchereau, J. (2007) Dendritic cell subsets in health and disease. Immunological Reviews, 219, 118 142.